fanrastic crc read
http://csn.cancer.org/node/251562
AT THE ASHRAM
so many hugs and kind wishes, I am camping.
today I had my best yoga day yet. i also got into aerial yoga.
I had a good walk. I got up 4.30AM to meditate. Off to sleep now in my new tent near the ashram, immersed in nature, birds and trees.
I also have experienced severe pain from cramps, despite salt and magnesium.
I have been feeling daunted by the challenge, I so appreciate all the prayers and kindness, my heart is breaking under this pressure, in case you could not tell. I think the lack of support at the CIMT conference, and the feeling i am completely on my own is apart of this.
then I think how wonderful of god to give me such challenges to GROW, even if I die, I am proud of my achievements todate.
the good thing about being close to GOD, well he gives me the challenges and the next second, I say thanks heaps and OK well now help me find the answer that you have hidden in our magnificanetly designed healing biology.
PLEASE PRAY FOR ME, ALAS I AM HUMAN, VERY HUMAN AT TIMES AND FEELING THE PRESSURE OF PROGRESSION AGAIN ON TRIP 10.
In my heart I have confience, but living with possible progression and uncertainty, well it just comes with the territory
ANOTHER LETTER TO THE DOCTORS
I apologise in advance if these emails are long and confusing, I do my best to be concise, but these issues and complex and there are many factors and issues to clarify. This paper is a good summary of immune issues and tumour environment, its pancreatic cancer but similar issues exist for colorectal, in particular its lack of tumour antigenicity except in the case of MSI microsatellite instablity in the colorectal mutation which I dont have.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619061/ a good read! Please note the plasticity of TAMS that we suspect is repolarised by targeted and systemic gcmaf therapy.
http://www.ncbi.nlm.nih.gov/
I have added to this esteemed list of doctors Dr Carolyn Makin , one of the world experts in Frequency specific microcurrent (FSM). I attended her core training course two weeks ago. FSM is one of the additions to my regime I will discuss later. Note its not been tested for cancer indications and its not recommended, but off the record its use in my case is being observed with close scrutiny, its use is my initiative and I appreciate the support of FSM experienced Doctors. So FSM makes much clinical sense and has much potential, but also unquantified risks I seek to minimise. In the face of recent progression of course I am weary, but I have only been using groups of frequencies that hopefully support healing and that dont promote cancer.
I have used frequencies that heal LYMPHATICS, reduce CONCUSSION, boost IMMUNE FUNCTION, address liver toxicity, liver fibrosis, asthama and lung function, gut health and PTSD. as well as some specific treatments for the LYMPADEMA of my left foot, that was rapid onset an swellen and painful, last WEDNESDAY. Note am very aware that Prof Vogl treated suspect cancerous activity in my central drainage lymph nodes 4 weeks ago. So any lymphatic issues need to be thoroughly investigated. That said the Newcastle disease viral treatment of the lymphatics generated a 4 day cea rise from 91 to 400, so it was remarkably effective, and then 2 weeks later the cea came down to 84. So this is the die off spike I have seen many times before. so there is indication of treatment success, but no guarantee of complete treatment.
I copy all the doctors, as every single INCIDENCE of progression can be fatal and represents KEY clinical lessons for my ongoing management and those who follow in similar therapies. I hope to elucidate the issues I face, in particular the recurrant nature of my colorectal cancer.
I had the opportunity to talk with dr schilling and dr kopic today and will relay there points before I detail the regime.
I explained increasing flem and coughing over the last weeks, and said I was worried about mucositis ) aside effect from ipilumimab the ctla4 inhibitor I had mid february. I also relay In the last week I have had unusual bouts of diahrrea. After attending the CIMT conference I am aware of the deolayed onset immune side effects of CTLA4 and PD1 treatments, these are autoimmune in nature.
I need to get Hallwangs comment regarding BRAf- MEK inhibitors that have proven benefit to boost anitgenic of colorectal cancer. the implication is to use cetumimab before the next DC vaccine. There is also the potential to use AVASTIN locally in the next TACE proecedure, as well as GCMAF. Many of these options will be clarified and assessed in discussions over the next few weeks. Meanwhile my current focus to attempt to stop tumour progression by using GCMAF, FSM, and targetted infusions under Dr Schillings supervision and then fallback on previously successful therapies in the case I dont obtain ongoing disease control over the next 2 weeks.
Of course if the imaging reveals a TACE target, it will be destroyed at Prof Vogl earliest convenience, the only caveat in this might be delaying a week while a new DC booster vaccine is prepared. Subject to attempts to resolve current susepct LUNG and COLON inflammation, driving very high CRP and ESR.
THE CURRENT REGIME
Daily 250ml GCMAF yogurt MAF314 with organic colostrum, daily with olive oil.Sometimes a morning yogurt enema with added probiotics.
Evening BRAVO suppository, after a coffee enema generally. I have 10 boxes of these suppositories and planned on one per night. Its expected this dosage would deliver AMPLe gcmaf for my low level micrometastatic illness. Note we have only been doing this regime 1 week.
Today I have started taking XELODA chemo ( been off this 3 months ) 1000mg mornings and nights. To see if this assists with disease control and provides some antigens for the immune system. Agreed with Dr Schilling today.
Supplements and off labels
Cimetidine, metformim, celebrex, asprin, curcumin, boswelia, ahcc, coriolous, iodine. many others, but these are the main anticancer.
I have been doing once per week these infusions B17, DMSO, IV CURCUMIN, GERMANIUM. Looking at increasing these.
Tuesday back to ongoing anti cancer infusions MUNICH with Dr Schilling and supportive care Dr Horger.
OP4: COMBINATION THERAPY WITH BAMLET AND THE TLR7 AGONIST R848 PROTECTS AGAINST MELANOMA
IN A MURINE MODEL
L Dyck
1
, N Harte
1
, KH Mok
1
, KHG Mills
1
1
School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
BAMLET, a bovine alpha-lactalbumin - oleic acid complex, is a novel and promising candidate for the treatment of cancer
because of its capacity to specifically kill cancer cells while leaving normal cells and tissues relatively unharmed. While
recent studies focused on direct tumouricidal effects of BAMLET, we investigated the potential of BAMLET to modulate
immune responses against tumour cells, in combination a TLR agonist, which also has anti-tumour activity by virtue
of its ability to non-specifically stimulate innate and adaptive immune responses. We examined the protective efficacy
of BAMLET and the TLR-7 agonist R848 in the B16 melanoma murine tumour model and investigated the underlying
mechanism of action. Consistent with previous studies, BAMLET induced killing of B16 melanoma cells but not normal
cells in vitro. Moreover, BAMLET and R848 strongly activated dendritic cells (DCs) which are crucial for the induction of
adaptive immune responses against tumours. Treatment of tumour bearing mice with either BAMLET or R848 s.c. in the
area of the tumour (days 3, 7, 10 and 14) induced some protection against tumour growth. However, the combination of
BAMLET and R848 conferred a high level of protection, with 57% of mice completely rejecting the tumour. We found a
higher frequency of IFN-gamma-secreting CD4 T cells and an increased frequency of DCs in the tumour draining lymph
nodes (LN) and spleens of mice treated with the combination of BAMLET and R848, compared with untreated mice or
mice treated with either BAMLET or R848 alone. Our data are consistent with a role for BAMLET in directly killing tumour
cells which release antigens that are taken up by DCs, but also suggest that BAMLET can promote DC maturation,
especially when co-activated through a TLR. These activated DCs promote induction of IFN-gamma-secreting CD4 T
cells that have anti-tumour activity. In conclusion, we demonstrated that BAMLET and R848 are a promising combination
therapy against cancer as they target tumour cells directly and activate anti-tumour immune responses